New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
07:27 EDTCBLICleveland BioLabs reports Q3 EPS (30c) vs (8c) in Q3 of 2011
Reports Q3 R&D expenses down to about $4.8M. Revenues for Q3 decreased to approximately $0.2M from approximately $3.8M in Q3 of 2011, primarily due to decreases in research sponsored by the DoD, BARDA and a NY State/RPCI Sponsored Research Agreement.
News For CBLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
08:15 EDTCBLICleveland BioLabs initiates colorectal cancer study of entolimod in Russia
Cleveland BioLabs announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in treatment-naive patients with primary colorectal cancer who are recommended for surgery. The primary objective of the study is to determine the optimal dose and dosing regimen for treatment of these patients with entolimod prior to surgery. Secondary objectives include evaluation of pharmacodynamic parameters, including immune response to single or double administrations of entolimod at varying dose levels. Up to 32 patients are expected to be enrolled in the study, which is being conducted at four leading oncology centers in the Russian Federation. The study is supported by a development contract with the Russian Federation Ministry of Industry and Trade.
January 29, 2016
16:50 EDTCBLICleveland BioLabs files to sell 6.72M shares of common stock for holders
Subscribe for More Information
January 26, 2016
07:40 EDTCBLICleveland BioLabs announces start of Phase 2 study of CBLB612 in Russia
Cleveland BioLabs announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. CBLB612 is a synthetic lipopeptide that activates pro-survival and immunoregulatory signaling pathways via specific binding to Toll-like receptors 2 and 6 that are present on a subset of body tissues and cell types that express this receptor. The study will primarily assess whether CBLB612 will ameliorate the myelosuppressive effects of doxorubicin-cyclophosphamide chemotherapy. Patients with breast cancer will be randomized into one of three arms: to receive placebo given before and after chemotherapy, to receive a single dose of CBLB612 given before chemotherapy, or to receive a single dose of CBL612 given after chemotherapy. The study will evaluate CBLB612 effects on the depth and duration of chemotherapy-induced neutropenia and thrombocytopenia. The trial will also assess changes in the numbers of circulating bone marrow progenitor cells and reticulocytes, the concentrations of plasma cytokines, and CBLB612 safety. At least 39 evaluable patients are expected to be enrolled into the study, which is being conducted at up to six leading oncology centers in the Russian Federation. The study is supported by a development contract with the Russian Federation Ministry of Industry and Trade.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use